DrugPatentWatch Database Preview
Etanercept - Biologic Drug Details
» See Plans and Pricing
Summary for etanercept
Tradenames: | 1 |
Patents: | 378 |
Applicants: | 1 |
BLAs: | 1 |
Suppliers: see list | 2 |
Recent Clinical Trials: | See clinical trials for etanercept |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for etanercept |
Recent Clinical Trials for etanercept
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 1 |
Duke University | Phase 1 |
Anelixis Therapeutics, Inc. | Phase 2 |
Recent Litigation for etanercept
Identify key patents and potential future biosimilar entrants
District Court Litigation
Case Name | Date |
---|---|
Celgene Corporation v. Mylan Pharmaceuticals Inc. | 2020-01-02 |
CELGENE CORPORATION v. MYLAN PHARMACEUTICALS INC. | 2019-12-30 |
CELGENE CORPORATION v. HETERO LABS LIMITED | 2019-07-16 |
PTAB Litigation
Petitioner | Date |
---|---|
Dr. Reddy's Laboratories, Inc. | 2018-08-03 |
2014-11-06 | |
2013-08-15 |
Pharmacology for etanercept
Mechanism of Action | Tumor Necrosis Factor Receptor Blocking Activity |
Company Disclosures: US Patents for etanercept
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Immunex Corporation (Seattle, WA) | 2012-03-07 | RX | Orphan | company |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Immunex Corporation (Seattle, WA) | 2014-02-25 | RX | Orphan | company |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Immunex Corporation (Seattle, WA) | 2009-09-05 | RX | Orphan | company |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Immunex Corporation (Seattle, WA) | 2009-09-11 | RX | Orphan | company |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | 2009-09-05 | RX | Orphan | company | |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Immunex Corporation (Seattle, WA) | 2009-09-05 | RX | Orphan | company |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for etanercept
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Massachusetts Eye and Ear Infirmary (Boston, MA) | 2034-06-16 | RX | Orphan | search |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | Orphan | search |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Knopp Biosciences LLC (Pittsburgh, PA) | 2033-08-13 | RX | Orphan | search |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | Coherus Biosciences, Inc. (Redwood City, CA) | 2039-02-26 | RX | Orphan | search |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | LUPIN LIMITED (Mumbai, Maharashtra, IN) | 2032-10-26 | RX | Orphan | search |
Immunex | ENBREL | etanercept | VIAL; SUBCUTANEOUS | 103795 | 001 | 1998-11-02 | Start Trial | The William M. Yarbrough foundation (Peoria, IL) | 2032-07-26 | RX | Orphan | search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for etanercept
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 2015028087 | Start Trial |
Canada | 2478731 | Start Trial |
Australia | 2015258859 | Start Trial |
Denmark | 2295081 | Start Trial |
Germany | 602004017608 | Start Trial |
Canada | 2436659 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for etanercept
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
2017 00012 | Denmark | Start Trial | PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2015)4704 20150707 |
2015 016 | Romania | Start Trial | PRODUCT NAME: IBRUTINIB SAU O SARE FARMACEUTIC ACCEPTABILA A ACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/14/945; DATE OF NATIONAL AUTHORISATION: 20141021; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/945; DATE OF FIRST AUTHORISATION IN EEA: 20141021 |
01930044 | Spain | Start Trial | PRODUCT NAME: APREMILAST O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/14/981; DATE OF AUTHORISATION: 20150115; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/981; DATE OF FIRST AUTHORISATION IN EEA: 20150115 |
19C/008 | Belgium | Start Trial | PRODUCT NAME: APREMILAST,OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/14/981 20150116 |
2017 00061 | Denmark | Start Trial | PRODUCT NAME: SARILUMAB; REG. NO/DATE: EU/1/17/1196/001-8 20170627 |
1 | Finland | Start Trial | |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |